• Users Online: 385
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
ORIGINAL ARTICLE
Year : 2019  |  Volume : 4  |  Issue : 3  |  Page : 296-301

Diagnostic value of posttherapy brain single photon emission computed tomography/computed tomography with pentavalent 99mTc dimercaptosuccinic acid in patients with glioblastoma multiform: preliminary report


1 Department of Nuclear Medicine, South Egypt Cancer Institute, Assuit, Egypt; Department of Radiology, University of California, Davis, California, USA
2 Department of Oncology and Nuclear Medicine, Assuit University Hospital, Assuit, Egypt
3 Department of Neurosurgery, Assuit University Hospital, Assuit, Egypt

Correspondence Address:
Nsreen R Ali
Department of Oncology and Nuclear Medicine, Assiut University Hospital, Assiut University, Banny Mour, Elfatah, Assuit, Postal Code: 02088
Egypt
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/JCMRP.JCMRP_65_19

Rights and Permissions

Aim To evaluate the feasibility of performing 99mTc dimercaptosuccinic acid (DMSA) (V) brain single photon emission computed tomography/computed tomography (SPECT/CT) in patients with glioblastoma multiform after their definitive therapy. Patients and methods Patients with documented grade IV glioma were prospectively recruited for this study. 99mTc-DMSA (V) brain SPECT/CT imaging was acquired after a mean interval of 76 ± 46 days from therapy, 2–3 h. After intravenous injection of 555–740 mBq of the tracer. Scans were interpreted visually as positive or negative by three nuclear medicine physicians. Agreement between two or more physicians was considered a consensus decision. The consensus results of DMSA (V) SPECT/CT were compared against the reference standard which was based on subsequent clinical/neuroimaging follow up or pathology whenever resurgery is performed. Lesion quantitation was performed by one nuclear medicine physician by drawing a region of interest on the lesion site (L) and a mirror region of interest on the contralateral normal brain tissue (NL) then L/NL ratio was calculated. Results A total of 20 patients were enrolled in this study. According to the reference standard, recurrence was detected in 10 patients while 10 were disease free. Interreader kappa agreement ranged from 0.65 to 0.90. Consensus reading of DMSA (V) SPECT/CT correctly detected recurrence in 8/10 (sensitivity 80%) and correctly ruled out disease in 9/10 (specificity 90%). L/NL ratio for positive and negative cases were 6.6 ± 8 and 1.3 ± 1.1, respectively (P < 0.001). Conclusion 99mTc-DMSA (V) brain SPECT/CT is feasible and may be a specific noninvasive diagnostic tool for the follow-up of patients with glioblastoma multiform after chemoradiotherapy.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed110    
    Printed8    
    Emailed0    
    PDF Downloaded19    
    Comments [Add]    

Recommend this journal